FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.

Jamet B, Ahrari S, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj K, Itti E, Karlin L, Bailly C, Levin MD, Minnema MC, Bodet-Milin C, de Keizer B, Corre J, Sonneveld P, Mateus D, Moreau P, Touzeau C, Kraeber-Bodéré F, Carlier T

Open source

DOI: 10.1182/bloodadvances.2025019465
Published: 2026 Jun 9
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025019465,
  title = {FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.},
  author = {Jamet B and Ahrari S and Zweegman S and Perrot A and Hulin C and Caillot D and Facon T and Leleu X and Belhadj K and Itti E and Karlin L and Bailly C and Levin MD and Minnema MC and Bodet-Milin C and de Keizer B and Corre J and Sonneveld P and Mateus D and Moreau P and Touzeau C and Kraeber-Bodéré F and Carlier T},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025019465},
  url = {https://doi.org/10.1182/bloodadvances.2025019465}
}

RIS

TY  - JOUR
TI  - FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.
AU  - Jamet B
AU  - Ahrari S
AU  - Zweegman S
AU  - Perrot A
AU  - Hulin C
AU  - Caillot D
AU  - Facon T
AU  - Leleu X
AU  - Belhadj K
AU  - Itti E
AU  - Karlin L
AU  - Bailly C
AU  - Levin MD
AU  - Minnema MC
AU  - Bodet-Milin C
AU  - de Keizer B
AU  - Corre J
AU  - Sonneveld P
AU  - Mateus D
AU  - Moreau P
AU  - Touzeau C
AU  - Kraeber-Bodéré F
AU  - Carlier T
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025019465
UR  - https://doi.org/10.1182/bloodadvances.2025019465
ER  -

APA

B, J., S, A., S, Z., A, P., C, H., D, C., T, F., X, L., K, B., E, I., L, K., C, B., MD, L., MC, M., C, B., B, D. K., J, C., P, S., D, M., P, M., C, T., F, K., & T, C. (2026). FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.. Blood advances. https://doi.org/10.1182/bloodadvances.2025019465

Source records

pubmed · retrieved 2026-09-27T14:17:29.464Z